Everolimus Approved for HR-Positive Breast Cancer

被引：2
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2012年 / 2卷 / 09期
关键词：
D O I：
10.1158/2159-8290.CD-NB2016-162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：756 / 756
页数：1
相关论文
共 50 条
  • [41] Clinical validity of CTS5 for late recurrence in Chinese patients with early HR-positive breast cancer
    Xu, Junnnan
    Sun, Tao
    CANCER RESEARCH, 2020, 80 (04)
  • [42] Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success
    Cazzaniga, Marina Elena
    Danesi, Romano
    Girmenia, Corrado
    Invernizzi, Pietro
    Elvevi, Alessandra
    Uguccioni, Massimo
    Gila, Monica Perez
    Amaducci, Laura
    Atzori, Francesco
    Blasi, Livio
    Butti, Chiara
    Collova, Elena
    De Conciliis, Enrico
    Fabi, Alessandra
    Febbraro, Antonio
    Garrone, Ornella
    Gianni, Lorenzo
    Giotta, Francesco
    La Verde, Nicla
    Michelotti, Andrea
    Palumbo, Raffaella
    Paris, Ida
    Pistelli, Mirco
    Pizzuti, Laura
    Rubino, Daniela
    Valerio, Maria Rosaria
    Zustovich, Fable
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (03) : 483 - 494
  • [43] Factors predictive of response to neo-adjuvant hormone therapy in elderly patients with HR-positive breast cancer
    Zoubir, Mustapha
    Andre, Fabrice
    Rouzier, Roman
    Conforti, Rosa
    Garbay, Jean-Remi
    Spielmann, Marc
    Mathieu, Marie-Christine
    Vielh, Philippe
    Marsiglia, Hugo
    Delaloge, Suzette
    ANNALS OF ONCOLOGY, 2006, 17 : 159 - 159
  • [44] Retrospective single case reports on the treatment of patients with HER2-positive/HR-positive early breast cancer with neratinib (IRENE)
    Tribian, N.
    Goehler, T.
    Baesecke, J.
    Guth, D.
    Vannier, C.
    Petru, E.
    Maass, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 171 - 171
  • [45] PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
    Ascione, Liliana
    Zagami, Paola
    Nicolo, Eleonora
    Crimini, Edoardo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (11):
  • [46] HEALTH UTILITIES FOR PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER: A SYSTEMATIC LITERATURE REVIEW
    da Silva, Aniceto C.
    Cueto, J.
    Salvo, E. M.
    Samjoo, I. A.
    Law, E. H.
    VALUE IN HEALTH, 2020, 23 : S445 - S445
  • [47] Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer
    Ettl, Johannes
    BREAST CARE, 2016, 11 (03) : 174 - 176
  • [48] ECONOMIC ASSESSMENT OF RIBOCICLIB FOR THE TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCER HR-POSITIVE, HER2-NEGATIVE
    Velasquez, M.
    Medina, Bustos L.
    Chacon, Zagarra C.
    Rojas, R.
    VALUE IN HEALTH, 2022, 25 (01) : S84 - S84
  • [49] Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wang, Wei
    Lei, Wenqian
    Fang, Ziru
    Jiang, Ruiyuan
    Wang, Xiaojia
    BMC CANCER, 2024, 24 (01)
  • [50] RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients
    Wang, Haibo
    Ma, Li
    Zhang, Yanan
    Wang, Ouchen
    Wei, Zhimin
    Xie, Xiaohong
    Zha, Xiaoming
    Zeng, Jian
    Lv, Qing
    Ren, Yu
    Wang, Huimin
    Du, Furong
    Cao, Shangzhi
    FRONTIERS IN ONCOLOGY, 2022, 12
12345